Department of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, PR China.
Department of Laboratory Medicine, Xuzhou Medical University Affiliated Hospital of Lianyungang, Lianyungang, PR China.
Clin Biochem. 2021 May;91:52-58. doi: 10.1016/j.clinbiochem.2021.02.004. Epub 2021 Feb 20.
Six medical testing laboratories at six different sites in China participated in this study. We applied a six sigma model for (a) the evaluation of the analytical performance of serum enzyme assays at each of the laboratories, (b) the design of individualized quality control programs and (c) the development of improvement measures for each of the assays, as appropriate.
Internal quality control (IQC) and external quality assessment (EQA) data for selected serum enzyme assays were collected from each of the laboratories. Sigma values for these assays were calculated using coefficients of variation, bias, and total allowable error (TEa). Normalized sigma method decision charts were generated using these parameters. IQC design and improvement measures were defined using the Westgard sigma rules. The quality goal index (QGI) was used to assist with identification of deficiencies (bias problems, precision problems, or their combination) affecting the analytical performance of assays with sigma values <6.
Sigma values for the selected serum enzyme assays were significantly different at different levels of enzyme activity. Differences in assay quality in different laboratories were also seen, despite the use of identical testing instruments and reagents. Based on the six sigma data, individualized quality control programs were outlined for each assay with sigma <6 at each laboratory.
In multi-location laboratory systems, a six sigma model can evaluate the quality of the assays being performed, allowing management to design individualized IQC programs and strategies for continuous improvement as appropriate for each laboratory. This will improve patient care, especially for patients transferred between sites within multi-hospital systems.
本研究在中国六个不同地点的六个医学检测实验室开展。我们应用六西格玛模型,(a)评估各实验室血清酶检测的分析性能,(b)设计个体化质量控制方案,(c)针对每个检测项目,制定适当的改进措施。
从各实验室收集选定的血清酶检测的内部质量控制(IQC)和室间质量评价(EQA)数据。使用变异系数、偏倚和总允许误差(TEa)计算这些检测的西格玛值。使用这些参数生成归一化西格玛法决策图。使用 Westgard 西格玛规则定义 IQC 设计和改进措施。质量目标指数(QGI)用于协助识别影响分析性能的缺陷(偏倚问题、精密度问题或其组合),这些缺陷会影响西格玛值<6 的检测。
选定的血清酶检测的西格玛值在不同的酶活性水平上存在显著差异。尽管使用了相同的检测仪器和试剂,不同实验室的检测质量也存在差异。根据六西格玛数据,为每个实验室西格玛值<6 的每个检测制定了个体化的质量控制方案。
在多地点实验室系统中,六西格玛模型可以评估正在进行的检测质量,使管理部门能够设计个体化的 IQC 方案和持续改进策略,以适应每个实验室的情况。这将改善患者的治疗效果,尤其是对于在多医院系统内不同地点之间转院的患者。